Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-22-000123
Filing Date
2022-08-08
Accepted
2022-08-08 16:06:10
Documents
56
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20220630.htm   iXBRL 10-Q 1817942
2 EX-31.1 exhibit311q22022.htm EX-31.1 9996
3 EX-31.2 exhibit312q22022.htm EX-31.2 10016
4 EX-32.1 exhibit321q22022.htm EX-32.1 5654
5 EX-32.2 exhibit322q22022.htm EX-32.2 5783
  Complete submission text file 0001714899-22-000123.txt   6502284

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20220630.xsd EX-101.SCH 38160
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20220630_cal.xml EX-101.CAL 54234
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20220630_def.xml EX-101.DEF 177211
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20220630_lab.xml EX-101.LAB 481393
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20220630_pre.xml EX-101.PRE 318995
50 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20220630_htm.xml XML 1062804
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 221144318
SIC: 2836 Biological Products, (No Diagnostic Substances)